Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
2.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

3.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

4.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

PMID:
25173516
5.

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators.

Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
22572202
6.

Apixaban versus warfarin in patients with atrial fibrillation.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators.

N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.

7.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

8.

[Current status of secondary prevention and cardiac rehabilitation programs in Spain].

Plaza Pérez I.

Rev Esp Cardiol. 2003 Aug;56(8):757-60. Spanish. No abstract available.

9.

[Recommendations for the control of cholesterolemia in Spain].

Villar Alvarez F, Mata López P, Plaza Pérez I, Pérez Jiménez F, Maiques Galán A, Casasnovas Lenguas JA, Banegas Banegas JR, Abadal LT, Rodríguez Artalejo F, Gil López E.

Rev Esp Salud Publica. 2000 Sep-Dec;74(5-6):457-74. Spanish.

10.

[Cholesterolemia control in Spain, 2000: a tool for cardiovascular disease prevention].

Plaza Pérez I, Villar Alvarez F, Mata López P, Pérez Jiménez F, Maiquez Galán A, Casasnovas Lenguas JA, Banegas Banegas JR, Tomás Abadal L, Rodríguez Artalejo F, Gil López E.

Rev Clin Esp. 2000 Sep;200(9):494-515. Review. Spanish.

PMID:
11111397
11.

[Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention].

Plaza Pérez I, Villar Alvarez F, Mata López P, Pérez Jiménez F, Maiquez Galán A, Casasnovas Lenguas JA, Banegas Banegas JR, Tomás Abadal L, Rodríguez Artalejo F, Gil López E.

Rev Esp Cardiol. 2000 Jun;53(6):815-37. Review. Spanish.

12.

[Documents of cardiovascular prevention: a global view].

Plaza Pérez I, Brotons Cuixart C, Mata López P, Luque Otero M, Arnalich Fernández F, Villar Alvarez F, Wood D.

Rev Esp Cardiol. 2000 Jun;53(6):773-5. Spanish. No abstract available.

13.

[Attitude change of Spanish cardiologist with respect to hypolipidemic treatment in secondary prevention. The role of outside hospital care].

Plaza Pérez I, Taboada Taboada M, Bautista Herrero Jimeno J, Gómez Guindal JA, Román León MT.

Rev Esp Cardiol. 1998;51 Suppl 6:54-62. Spanish.

14.

[Secondary prevention and cardiac rehabilitation in Spain. Section of Preventive Cardiology].

Plaza Pérez I, Velasco Rami JA, Maroto Montero JM.

Rev Esp Cardiol. 1996 Aug;49(8):549-53. Spanish.

PMID:
8756199
17.

[Prevalence of breast feeding and its relation to cardiovascular risk factors in the pediatric population of Fuenlabrada].

Cobaleda Rodrigo A, Hidalgo Vicario MI, Plaza Pérez I, Muñoz Calvo MT, López Martínez D, Otero de Becerra J, Baeza Mínguez J, Ruiz Jarabo C, Madero Medrano R, Parra Martínez I, et al.

An Esp Pediatr. 1989 Oct;31(4):350-5. Review. Spanish.

PMID:
2697163
18.

[The Fuenlabrada study: lipids and lipoproteins in children and adolescents].

López Martínez D, Plaza Pérez I, Muñoz Calvo MT, Madero Medrano R, Otero de Becerra J, Hidalgo Vicario I, Baeza Mínguez J, Ceñal González-Fierro MJ, Cobaleda Rodrigo A, Parra Martínez I, et al.

An Esp Pediatr. 1989 Oct;31(4):342-9. Review. Spanish.

PMID:
2697162
19.

[The Fuenlabrada study: normal values of arterial pressure in children and adolescents].

Muñoz Calvo MT, Plaza Pérez I, López Martínez D, Madero Medrano R, Otero de Becerra J, Hidalgo Vicario I, Cobaleda Rodrigo A, Parra Martínez I, Baeza Mínguez J, González-Fierro MJ, et al.

An Esp Pediatr. 1989 Oct;31(4):336-41. Review. Spanish.

PMID:
2697161
20.

[The Fuenlabrada study: smoking habits in children and adolescents. Effect on various cardiovascular risk factors].

Muñoz Calvo MT, Plaza Pérez I, Madero Medrano R, López Martínez D, Otero de Becerra J, Hidalgo Vicario I, Baeza Mínguez J, Ceñal González-Fierro MJ, Parra Martínez I, Cobaleda Rodrigo A, et al.

An Esp Pediatr. 1989 Oct;31(4):331-5. Review. Spanish.

PMID:
2697160

Supplemental Content

Loading ...
Support Center